What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?

References

• Rainer MK. Risperidone long-acting injection: A review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4:919–27.
   PubMedGoogle Scholar
• Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010;127:77–83.
   PubMedGoogle Scholar
• Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009;66:358–65.
   PubMed Web of Science ®Google Scholar
• El-Hage W, Surguladze SA. Emerging treatments in the management of bipolar disorder—Focus on risperidone long acting injection. Neuropsychiatr Dis Treat 2010;6:455–64.
   Web of Science ®Google Scholar
• Samalin L, Charpeaud T, Lorabi O, Llorca P. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: Focus on risperidone injection. Patient Prefer Adherence 2010;4:325–34.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé [Internet]. Guide d'analyse de la littérature et gradation des recommandations [updated 2000 Jan 1]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/analiterat.pdf
   Google Scholar
• ClinicalTrials.gov [Internet]. Paliperidone palmitate efficacy and safety in bipolar disorder complicated by alcohlism [updated 2010 Sep]. Available from: http://clinicaltrials.gov/ct2/show/NCT01211704?term = paliperidone+ bipolar&rank = 1
   Google Scholar
• ClinicalTrials.gov [Internet]. Efficacy, safety, and tolerability of an intramuscular formulation of aripiprazole (OPC-14597) as maintenance treatment in bipolar I patients [updated 2012 Oct 17]. Available from: http://clinicaltrials.gov/ct2/show/NCT01567527? term = aripiprazole+ depot+ bipolar&rank = 1
   Google Scholar
• Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827–39.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156–62.
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22:825–35.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand 2007; Suppl 434:50–6.
   Google Scholar
• Bobo WV, Epstein RA, Lynch A, Patton TD, Bossaller NA, Shelton RC. A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clin Neuropharmacol 2011;34:224–33.
   Google Scholar
• Benabarre A, Castro P, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Murru A, et al. Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder. Actas Esp Psiquiatr 2009;37:143–7.
   PubMed Web of Science ®Google Scholar
• Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006;26:530–1.
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry 2008;9:219–24.
   PubMed Web of Science ®Google Scholar
• Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1219–23.
   PubMed Web of Science ®Google Scholar
• Malempati RN, Bond DJ, Kunz M, Malemati C, Cheng A, Yatham LN. Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: A prospective study of 3-year outcomes. Int Clin Psychopharmacol 2011;26:146–50.
   Google Scholar
• Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: A 2-year study of 10 patients. Int Clin Psychopharmacol. 2008;23:88–94.
   PubMed Web of Science ®Google Scholar
• Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry 2011;11:1–10.
   Google Scholar
• Food and Drug Administration [Internet]. Risperdal Consta: Full Prescribing Information [updated 2011 Sep]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020272s060s066,020588s048s054,021444s035s042lbl.pdf
   Google Scholar
• Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P. Clinicians’ attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 2013;201:553–9.
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2012;12:259–69.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia?Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012;134:187–94.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Biswas K, Kilbourne AK, Fenn H, Williford W, Bauer MS. Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder. Psychiatr Serv 2008;59:753–9.
   PubMed Web of Science ®Google Scholar
• Coryell W. Rapid cycling bipolar disorder: Clinical characteristics and treatment options. CNS Drugs 2005;19:557–69.
   PubMed Web of Science ®Google Scholar
• Degenhardt EK, Gatz JL, Jacob J, Tohen M. Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord 2012;136:733–9.
   Google Scholar
• Garcia-Amador M, Colom F, Valenti M, Horga G, Vieta E. Suicide risk in rapid cycling bipolar patients. J Affect Disord 2009;117:74–8.
   Google Scholar
• Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263–72.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11: 81–109.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Lampe L, Paton M, O’Connor N, Newton LA, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand 2009; Suppl 439:27–46.
   Google Scholar
• Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: A review of the literature. Acta Psychiatr Scand 2007; Suppl 434:3–16.
   Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85–116.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11:225–55.
   PubMed Web of Science ®Google Scholar
• Henry C, Etain B. New ways to classify bipolar disorders: Going from categorical groups to symptom clusters or dimensions. Curr Psychiatry Rep 2010;12:505–11.
   PubMed Web of Science ®Google Scholar
• Coryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J. The significance of psychotic features in manic episodes: A report from the NIMH collaborative study. J Affect Disord 2001;67:79–88.
   PubMed Web of Science ®Google Scholar
• Dsm5.org [Internet]. Bipolar and related disorders [updated 2012 May]. Available from: http://www.dsm5.org/proposedrevision/Pages/BipolarandRelatedDisorders.aspx
   Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;373:31–41.
   PubMed Web of Science ®Google Scholar
• Leboyer M, Kupfer DJ. Bipolar disorder: New perspectives in health care and prevention. J Clin Psychiatry 2010;71:1689–95.
   PubMed Web of Science ®Google Scholar
• Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, et al. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Encephale 2009;35:330–9 . In French.
   PubMed Web of Science ®Google Scholar